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Gene expression signatures relating mammary stem
cell populations to breast cancers have focused on
adult tissue. Here, we identify, isolate, and charac-
terize the fetal mammary stem cell (fMaSC) state
since the invasive and proliferative processes of
mammogenesis resemble phases of cancer progres-
sion. fMaSC frequency peaks late in embryogenesis,
enabling more extensive stem cell purification than
achievedwith adult tissue. fMaSCsare self-renewing,
multipotent, and coexpress multiple mammary
lineage markers. Gene expression, transplantation,
and in vitro analyses reveal putative autocrine and
paracrine regulatory mechanisms, including ErbB
and FGF signaling pathways impinging on fMaSC
growth. Expressionprofiles from fMaSCsand associ-
ated stroma exhibit significant similarities to basal-
like and Her2+ intrinsic breast cancer subtypes. Our
results reveal links between development and cancer
and provide resources to identify new candidates for
diagnosis, prognosis, and therapy.
INTRODUCTION
Breast cancers are a heterogeneous group of diseases distin-
guishable by histopathology and molecular profiling. Expression
profiling of patient samples enabled their categorization into
molecular subtypes referred to as luminal A, luminal B, Her2
positive, basal-like, and claudin-low (Herschkowitz et al., 2007;
Perou et al., 2000). These divisions identify critical differences
in cellular composition and molecular pathways, suggesting
treatment options and correlating with patient survival (Prat
and Perou, 2011). Prognostic expression signatures, refined by
related approaches, are being tested or used clinically (Fan
et al., 2011; Paik et al., 2006; van ’t Veer et al., 2002; van de Vijver
et al., 2002). Previously reported prognostic signatures and
subtype designations identify a limited set of biologic programsCecorrelating with hormone receptor status (estrogen receptors
[ER] and progesterone receptors [PR]) and Her2 expression
and proliferation (Desmedt et al., 2008; Fan et al., 2006; Haibe-
Kains et al., 2008; Prat and Perou, 2011; Sotiriou and Piccart,
2007). While hormone receptors and Her2 are therapeutic
targets, many breast cancers, including most of the basal-like
subtypes, lack ER, PR, and Her2 expression and associated
targeted treatment options (Pal et al., 2011).
Stem cell biology offers promise for understanding the origins
and progression of breast and other cancers andmay also reveal
the next generation of molecular targets for breast cancers not
susceptible to current agents. For example, basal-like breast
cancers are poorly differentiated and exhibit gene expression
similarities to embryonic and induced pluripotent stem cells
(Ben-Porath et al., 2008; Mizuno et al., 2010). Expression profiles
derived from adult mammary cells of different differentiation
stages have also been used to designate cancers as stem-like
or nonstem-like (Lim et al., 2009; Lim et al., 2010; Perou et al.,
2010). Breast cancer cells that generate xenografted tumors
with high efficiency, regenerate the cellular complexity of the
originating tumor, and self-renew (as defined by secondary
transplantation) exhibit properties attributed to stem cells and
have consequently been called breast cancer stem cells
(Al-Hajj et al., 2003). However, defining potential relationships
between stem-like cells in breast cancer and normal mam-
mary stem cells (MaSCs) requires MaSC isolation and
characterization.
Adult MaSCs (aMaSCs) have been enriched via stem cell
isolation methods, and their gene expression signatures have
been reported (Lim et al., 2009; Lim et al., 2010; Pece et al.,
2010; Raouf et al., 2008; Shackleton et al., 2006; Stingl et al.,
2006). However, aMaSC rarity combined with the cellular
complexity of the adult gland make purification challenging
(Shackleton et al., 2006; Stingl et al., 2006), and copurifying
stroma and differentiated mammary cells complicate elucidation
of their core self-renewal and differentiation programs.
The developing mammary gland is less complex than the adult
gland, suggesting that it may facilitate stem cell identification
and purification. Furthermore, while the extensive proliferation,
migration, and invasion required for mammogenesis do not
occur in the resting adult mammary gland, they do resemblell Stem Cell 10, 183–197, February 3, 2012 ª2012 Elsevier Inc. 183
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2003). These observations suggest that stem cells present
in fetal mammary rudiments (i.e., fetal mammary stem cells
[fMaSCs]) might express genes comprising pathways over-
looked by analyses focused only on the adult mammary gland
and that fMaSCs may reveal new targets to aide detection,
prognosis, and treatment of breast cancers. Consistent with
this idea, gene expression profiling of bulk epithelium from early
mammogenesis revealed significant differences with the adult
epithelium (Wansbury et al., 2011). Importantly, this study did
not assess whether the profiled cells exhibited stem cell activity,
so the relevance of these signatures to fMaSCs remains to be
determined.
Mousemammary gland development begins at approximately
embryonic day (E)11.5 with a thickening of the ventral ectoderm
to generate five pairs of mammary placodes. The placodes
become spherical buds by E12.5, which elongate into ductal
sprouts in females by E16 (Veltmaat et al., 2003). Invasion of
the extending rudiment into the fat pad precursor begins by
E16.5, and by E18.5 the mammary rudiment constitutes a primi-
tive branched network within the mammary fat pad (Veltmaat
et al., 2003).
Classic rudiment transplantation studies suggest that
mammary stem cells may arise coincident with the morphologic
specification of the mammary gland (Sakakura et al., 1979). For
example, transplanting multiple intact E13 to E17 epithelial rudi-
ments generated full mammary outgrowths (Sakakura et al.,
1979). Heterotypic recombination experiments involving salivary
mesenchyme demonstrated that the mammary epithelium is
committed to develop into a mammary phenotype by E12.5
(Cunha and Hom, 1996).
Here, we quantify and characterize fMaSC activity during fetal
mammogenesis, and analyze the relationships between their
gene expression programs and those found in human breast
cancer. Our data reveal the unexpected finding that fMaSCs
are extremely rare in early embryogenesis but increase rapidly
as the mammary rudiment invades into the fat pad precursor.
We also show that fMaSCs and their associated stroma exhibit
gene expression programs related to those found in specific
forms of human breast cancer.
RESULTS
Mammary Stem Cells Are Rare Early but Increase
Dramatically during Late Fetal Mammogenesis
We used limiting dilution transplantation analyses (LDTA) to
measure mammary repopulating unit (MRU) frequency by using
single-hit Poisson statistical analyses (Bonnefoix et al., 1996; Hu
and Smyth, 2009; Stingl et al., 2006). Accordingly, fetal
mammary repopulating units (fMRU) must contain an fMaSC
but may additionally require other cells or components for
mammary outgrowth. However, as a single stem cell can
generate amammary gland (Shackleton et al., 2006), wewill refer
to fMaSC frequency when quantifying fMRUs.
We transplanted limiting dilutions of rudiment-derived cell
suspensions obtained at different developmental stages of
CD1 embryos into immune compromised CB17-SCID recipients
(Figure 1A, Table 1, and Table S1, available online) and in
parallel transplanted intact mammary rudiments including184 Cell Stem Cell 10, 183–197, February 3, 2012 ª2012 Elsevier Incsurrounding mesenchyme (Figures S1A and S1D). Single intact
mammary rudiments from as early as E12.5 transplanted at
frequencies >70%. In contrast, measurable fMaSC activity
was not evident in dissociated bulk mammary cell populations
prior to E15.5 (Figure 1A, Table S1D, Table 1, column 2, Table
S1, column 3, and Table S2). This was surprising as we trans-
planted 10,000 viable cells (epithelial and mesenchymal)
per fat pad, which is more than we estimate to be present in
a single rudiment (Figure 1A, Table 1, and Table S1, column 3).
While rudiment dissociation could have reduced repopulation
efficiency, especially if contextual cues analogous to niche
interactions (Spradling et al., 2001) are required for stem cell
function, identically dispersed E18.5 rudiment cells routinely
generated mammary outgrowths from 100 cells (Table S1,
column 3). Thus, fMaSC concentration increases dramatically
during fetal development (Figure 1A; Table 1, column 2, and
Table S1, column 3).
The importance of extracellular cues in stem cell function
(Spradling et al., 2001) prompted us to determine whether
Matrigel would increase fMaSC transplantation efficiency as it
does aMaSCs (Lim et al., 2009). While Matrigel significantly
increased the sensitivity of fMaSC detection, it still equated to
one or fewer stem cells per E13.5 rudiment (1/12,000 cells; Fig-
ure 1A, Table 1, column 3, and Table S1, column 4). fMaSC
activity peaked at E18.5, increasing to 1 in 60 cells with Matrigel,
a 14-fold increase compared to transplantation in its absence
(Figure 1A, Table 1, and Table S1). Thus, fMaSC concentration
increases at least 200-fold between E13.5 to E18.5 when
measured in the presence of Matrigel (Figure 1A and Table 1,
column 3). This reflects a striking 9-fold increase in fMaSC
abundance during the narrow developmental window between
E15.5–E16.5 (1 in 1,800 to 1 in 200, p < 0.001) (Figure 1A, Table
1, and Table S1).
These quantitative measurements of stem cell frequency
during embryogenesis reveal for the first time the surprising
finding that transplantable fMaSCs are rare early in mammogen-
esis but are abundant late. Furthermore, the fMaSC frequency in
unfractionated E18.5 embryonic mammary rudiments is 5-fold
higher than that obtained with bulk adult mammary cell popula-
tions measured under identical conditions (1 in 60 versus 1 in
300, p < 0.001) (Table 1 and Table S1). These differences may,
in part, reflect different contaminating epithelial and stromal
components within the cell populations obtained at different
stages. Nevertheless, the data indicate that mammary stem
cell frequency is higher in the E18.5 mammary rudiment than in
the adult gland. This facilitates their purification for subsequent
molecular analyses.
Stem Activity Is Restricted to a Unique Fetal Population
Expressing High Levels of CD24 and CD49f
aMaSCs can be enrichedwith fluorescence activated cell sorting
for surface markers such as CD24 (heat stable antigen [HSA])
and CD49f (a6 integrin) (Stingl et al., 2006). Both proteins
were expressed in the stromal and epithelial compartments of
E13.5 and E15.5 mammary rudiments (Figure 1B). In contrast,
high CD24 and CD49f expression at E18.5 identifies a basal-
epithelial compartment with negligible staining in the fat pad
and surrounding mesenchyme, suggesting the utility of these
markers for fMaSC enrichment (Figure 1B). Consistent with.
Figure 1. fMaSCs Identified in Late Embryo-
genesis Express High Levels of CD24 and
CD49f
(A) Mammary stem cell frequency estimates at
various stages of fetal development and in the
adult in the presence or absence of Matrigel.
Gross morphological appearance of the gland at
various stages is illustrated. The following abbre-
viations are used: e = epithelium, m = mesen-
chyme, and fp = fat pad. *p < 0.001, pairwise
group difference. The error bars indicate 95%
confidence intervals (CI).
(B) Confocal images showing CD49f (i–iii) and
CD24 (iv–vi) expression in whole mounts at E13.5,
E15.5, and E18.5.
(C) Histogram and FACS contour plot showing
the distribution of cells expressing CD24 and
CD49f in the LIN population (DAPICD31
CD45TER119) in mammary glands from
a nulliparous adult mouse (black) and actin-eGFP
E18.5 female embryos (green). Adult eGFP
mammary and eGFP+ E18.5 fetal mammary cell
suspensions weremixed, costained, and analyzed
together.
(D) Immunofluorescence analysis of paraffin
sections of a regenerated mammary gland from
a parous recipient showing casein/K8 (i) and K14/
K8 (ii). The inset shows a secondary antibody
control.
(E) Representative FACS dot plots showing very
similar patterns of expression of CD24 and
CD49f in viable lineage-depleted mammary cells
from a nulliparous adult mouse (top) and from a
mammary gland regenerated by the fMaSCs
(bottom).
(F) Representative whole mount of actin-eGFP
mammary outgrowth arising from transplantation
of the fMaSC population (LinCD24highCD49fhigh)
isolated from E18.5 embryos. The mammary
glands were harvested from primary (i) and
secondary (ii) recipients 12 weeks after trans-
plantation. See also Table 1, Table S1, and Fig-
ure S1.
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rudiment cells expressed CD24 and CD49f (Figure S1B). At
E18.5, however, these markers delineate a distinct subpopula-
tion comprising approximately 5% of the cells following theCell Stem Cell 10, 183–197exclusion of endothelial and hematopoi-
etic lineages (Figure 1C and Figure S1B).
We then compared the CD24 and CD49f
staining profiles of admixed and copro-
cessed eGFP adult and eGFP+ E18.5
fetal mammary cells (Figure 1C). Cells
derived from E18.5 rudiments express
higher levels of CD24 than the previously
reported CD24medCD49fhigh aMaSC-
enriched population and higher levels of
CD49f than the CD24highCD49flow adult
luminal CFC population (colony-forming
cells) (Figure 1C) (Stingl et al., 2006).
This direct comparison with adultmammary cells shows that the fetal population is CD24high
CD49fhigh.
The CD24highCD49fhigh subpopulation contained all fMaSC
activity by transplantation analyses (Figure 1A and Table 1)., February 3, 2012 ª2012 Elsevier Inc. 185
Table 1. Fetal Mammary Rudiments in Late Embryogenesis Are Found to Be Highly Enriched with Mammary Stem Cells
Bulk Mammary Cells
MaSC Frequency (95% CI)
No Matrigel Coinjected with Matrigel
E13.5a <1/40,000 1/12,000 (1/5000 to 1/30,000), p = 0.2
E15.5a <1/4,000 1/1,800 (1/800 to 1/4,000), p = 0.9
E16.5a ND 1/200 (1/70 to 1/400), p = 0.68
E18.5a,b 1/830c (1/400 to 1/1,600), p = 0.8 1/60c (1/40 to 1/80), p = 0.7
Adultb 1/30,000d (1/11,000 to 1/80,000), p = 0.2 1/300 (1/150 to 1/500), p = 0.2
Fetal MaSC population (CD24highCD49fhigh) 1/400d (1/100 to 1/1,700), p = 0.2 1/14c (1/10 to 1/18), p = 0.7
Fetal fSTR population (CD24med/low/neg) <1/9,000 <1/5,000e
Adult MaSC population (CD24medCD49fhigh) 1/800d (1/200 to 1/2,700), p = 0.4 1/50 (1/30 to 1/100), p = 0.98e
p > 0.05 for frequency estimates indicates the data are consistent with a single-hit Poisson model. ND is an abbreviation for not determined.
a p < 0.001, pairwise group difference.
b p < 0.001, pairwise group difference.
c p < 0.001, pairwise group difference.
d These values represent rough MaSC frequency estimate (see Statistical Analyses for detail).
e p < 0.001, pairwise group difference.
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Fetal Mammary Stem Cells and Breast CancerThe remaining fetal population exhibits lower CD24 levels, is
devoid of fMaSC activity, and is enriched in stromal cells as
defined by cellular morphology and protein and gene expression
analyses (see below). Therefore, we call this population the fetal
stroma-enriched population (fSTR). As few as five to ten fMaSCs
reproducibly enabled robust mammary gland repopulation,
while up to 3,000 cells from the fSTR consistently failed to
generate outgrowths, even with Matrigel addition (Figure 1A,
Table 1, and Table S1). We estimate the stem cell frequency in
the fMaSC-enriched population to be 1 in 14 with Matrigel
(Table 1, Table S1, and Figure 1A), which is an 4-fold enrich-
ment over the aMaSC frequency when immune-compromised
hosts were used in the presence of Matrigel (1/50 [aMaSC]
versus 1/14 [fMaSC], p < 0.001; Table 1 and Table S1). Impor-
tantly, the aMaSC frequency in Matrigel when allotransplanta-
tion into immune-compromised hosts was used was similar to
that obtained with an immune competent, syngeneic model
(C57BL6) in the absence of Matrigel (Tables S1 and S3), and
host immune competence did not significantly affect fMaSC
frequency in the presence of Matrigel (Table S3).
fMaSCs generated morphologically normal, fully arborized
ductal structures that produced casein-positive alveolar struc-
tures upon induction of pregnancy (Figure 1D). Mammary
outgrowths exhibited the expected localized expression of
luminal and myoepithelial keratins (K8 and K14, respectively)
(Figure 1D), the phenotypic cellular heterogeneity of wild-type
adult mammary glands (Figure 1E), and contained cells able to
self-renew based on serial transplantation analyses (Figure 1F).
Thus, the fMaSC-enriched population exhibits the multi-lineage
cell differentiation and self-renewal characteristics expected of
mammary stem cells, but at considerably higher concentration
than found in the adult (Shackleton et al., 2006; Stingl et al., 2006).
fMaSCs Are Multipotent and Coexpress Markers
of Multiple Mammary Lineages
We evaluated the ability of individual fMaSCs to generate
multiple lineages in vitro (Dontu et al., 2003). While fMaSCs
had negligible sphere-forming efficiency (SFE) with a conven-
tional nonadherent sphere-forming protocol at low seeding186 Cell Stem Cell 10, 183–197, February 3, 2012 ª2012 Elsevier Incdensity (1,000 cells per cm2) (SFE 0.1%; Figures 2A and 2B),
fSTR formed numerous spherical clusters under identical condi-
tions (SFE = 1.4%) (Figures 2A and 2B). However, just asMatrigel
profoundly increased transplantation efficiency, even low per-
centages of Matrigel (2%) enabled the fMaSC population to
generate spheres with an SFE of 9.4% when plated at low
density (Figures 2A and 2B). The primary fMaSC-derived
spheres were morphologically similar to the colonies previously
reported for the aMaSC population (Figure 2A) (Stingl et al.,
2006). In addition, fMaSC-derived primary spheres expressed
markers associated with both myoepithelial (e.g., cytokeratin
14 [K14]) and luminal (cytokeratin 8 [K8]) epithelial lineages of
the mammary gland (Figure 2C).
We used two independent strategies to determine whether
primary spheres arise from clonal expansion from a single cell
or from cell aggregation. First, we seeded single cells from the
fMaSC population into individual wells. Primary spheres formed
(SFE = 10.7%) in 2%Matrigel, similar to the 9.4% SFE observed
when the cells were plated at low density (Figure 2B and Fig-
ure S2A). Secondary and tertiary spheres were also formed
with similar SFEs (10%; Figure 2B). The fSTR did not generate
spheres in the presence of Matrigel and instead produced
cultures of dispersed cells resembling fibroblasts and neurons
(Figures 2Aii and 2B). Second, wemixed single-cell suspensions
of eGFP+ and eGFP cells from the fMaSC population and then
grew them at low density (Figure 2B and Figure S2B). As 199 out
of 200 spheres were a single color, the vast majority must derive
from single cells (Figure S2C). Approximately 60% of fSTR-
derived clusters were overtly polyclonal when cultured in nonad-
herent conditions without Matrigel (Figure 2Aiii), indicating they
arise by aggregation. Taken together, these data show that
10% of the fMaSC population exhibits the stem cell properties
of multipotent differentiation and self-renewal in vitro (Figures 2B
and 2C).
Coexpression of proteins associated with multiple lineages
has been proposed to indicate plasticity in the normal mammary
gland and in breast cancers (Creighton et al., 2009; Livasy et al.,
2006; Petersen and Polyak, 2010; Sun et al., 2010; Thomas et al.,
1999). We detected cells that coexpress K14 and K8 from.
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and S2E). Approximately 30% of the cells within the fMaSC
population were K14+K8+, and we frequently detected such
double-positive cells in fMaSC-derived spheres (Figures 2C
and 2D). We also analyzed vimentin expression as it has been
associated with the myoepithelial and mesenchymal lineages
of the normal mammary gland and with aggressive disease
when coexpressed with luminal epithelial markers in breast
cancer patients (Creighton et al., 2009; Thomas et al., 1999).
Approximately 70% of cells within the K14+K8+ fMaSC popula-
tion also expressed vimentin (Figure 2D).
Derivation of fMaSC- and fSTR-Specific Gene
Expression Signatures
We performed microarray expression analyses on the fMaSC,
fSTR, and aMaSC populations to ascertain molecular pathways
with potential relevance to fetal mammary development, fMaSC
biology, and breast cancer. We obtained reproducible expres-
sion profiles from independent biological pools representing
each population and identified differentially expressed genes
comprising fMaSC, fSTR, and aMaSC signatures (Figure 3A
and Table S4; significance analysis of microarrays; false
discovery rate (FDR) < 10%; [Tusher et al., 2001]). We identified
869 unique genes more highly expressed in the fMaSC popula-
tion (the fMaSC signature) than in the fSTR and 812 unique genes
more highly expressed in the fSTR population (the fSTR signa-
ture) than in the fMaSC. Among the fMaSC signature genes,
34% were common to both the fMaSC and aMaSC popula-
tionswhen compared to fSTR, but40%were significantly over-
expressed in the fMaSC relative to the aMaSC (Figure 3A).
We confirmed the differential gene expression patterns
between the fMaSC and fSTR populations on a panel of genes
selected from putative stem cell, developmental, and cancer
relevant pathways (Figures 3B and 3C). Furthermore, high-
throughput single-cell qRT-PCR analyses confirmed expression
of a partially overlapping selection of 46 genes in individual cells
of the fMaSC population (Figure 3D). This approach also verified
that individual fetal cells coexpress luminal keratins, myoepithe-
lial keratins, and vimentin (Figure 3D).
Unique Expression Features of fMaSCs and fSTR
Manywell-studiedgeneswere found tobeexpressed in amanner
consistent with the cell types analyzed, indicating the validity of
the microarray data (Table S4). However, the fMaSC and fSTR
signatures revealed unique gene expression patterns when
compared to adult mammary populations or to those isolated
earlier in development that we showed to be lower in stem cell
content than the fMaSC population (Figures 1 and 4, Table 1,
and Tables S4 and S5). For example, qRT-PCR analysis showed
significant differences in expression of specific stem cell- and
development-related genes between the fMaSC and the E15.5
rudiment (Figure 4A). The gene content in the E18.5 fMaSC and
fSTR signatures were also significantly different from those re-
ported for either mouse or human adult mammary populations,
or from E12.5 mouse mammary epithelia (ME) and mammary
mesenchyme (MM) (Figures 4B–4D and Tables S4 and S5) (Ken-
drick et al., 2008; Lim et al., 2009; Lim et al., 2010; Pece et al.,
2010; Stingl et al., 2006; Wansbury et al., 2011). Although the
similarities between the fMaSC and previously reported primaryCemammary epithelial signatures are statistically significant, the
majority of genes in the fMaSC signature are not represented in
aMaSC signatures (Figure 4B). Surprisingly, the fSTR signature
is similar to the adult mammary stromal signature and to pub-
lished aMaSC signatures (Figure 4B).
We delineated genes specific to the fMaSC and fSTR popula-
tions by comparing their signatures to composite human/mouse
adult MaSC or stromal gene lists and to E12.5ME andMMsigna-
tures (Figure 4C). The sets of genes specific to the fMaSC and
fSTR signatures are rich in biological content as indicated by
their significant correlation with numerous gene ontology (GO)
categories (Figure 4D, Figure S4, and Tables S4 and S6). Among
these, cell signaling and genes associated with the plasma
membrane figure prominently (Figure 4D). A selection of the
most highly enriched clusters are detailed in Figure 4D, including
several genes previously implicated in mammary stem cell func-
tion and breast cancer, such as ErbB2 and ErbB4 (Korkaya and
Wicha, 2009). Several genes reciprocally expressed in the fSTR
and fMaSC populations are suggestive of paracrine signaling
and may contribute to stem cell behavior in normal or neoplastic
growth. For instance, the fSTR specific signature includes Nodal
and Wnt5a. Nodal is a TGF-b family morphogen that can pro-
mote oncogenic phenotypes in mammary cells and has been
implicated in breast and other cancers (Strizzi et al., 2009). The
Wnt5a protein is a noncanonical Wnt implicated in polarity,
migration and stem cell maintenance (Kikuchi et al., 2012). Addi-
tional processes found in both the fMaSC and fSTR populations
are likely to contribute to the unique properties of mammary cells
at this stage. For example, changes in chromatin regulation,
augmented synthetic metabolism and cell cycle, and the pro-
duction of distinctive extracellular matrices may contribute to
the robust fMaSC function we observe (Figure S4 and Table S4).
Cellular Interaction Is a Predicted Hallmark
of fMaSC Function
GO enrichment analysis of fetal signatures suggested a promi-
nent role for cell-cell and cell-niche interactions, including
cell surface receptor signaling in the fMaSC population (Figure 4
and Table S4). We used curated interaction networks in the
GeneGo pathway analysis platform to organize the genes
comprising the fMaSC and fSTR signatures into potential
receptor-ligand interactions. This enabled construction of a
hypothetical interaction map based on reported receptor-ligand
interactions (Figure 5A).
We determined whether predicted pathways are relevant for
fMaSC function in vitro (Figures 5B–5D and Figure S5). We
analyzed ErbB and FGF receptors and their ligands given their
cancer relevance and that growth of adult mammary epithelial
cells in vitro requires either EGF or FGF (Dontu et al., 2003).
qRT-PCR validated the differential expression of all four ErbB
family members, and the hormone receptors ER and PR (Fig-
ure S5A, and data not shown). ErbB4 was expressed at a low
level but exclusively in the fMaSC population (data not shown).
ErbB2 andErbB3were expressedmore highly in the fMaSCpop-
ulation than either the fSTR or aMaSC populations (Figure S5A),
and ErbB2 protein was detected in situ in CD24+ cells in E18.5
mammary rudiments (Figure S5B).
We examined the requirement for ErbB and FGF signaling
by growing fMaSC-derived spheres in 2% Matrigel culturell Stem Cell 10, 183–197, February 3, 2012 ª2012 Elsevier Inc. 187
Figure 2. Individual Cells from the fMaSC Population Generate Clonal, Multilineage Spheres that Can Be Serially Propagated and Coexpress
Markers of Multiple Lineages
(A) Morphology of structures generated from fMaSC (i) and fSTR (ii) populations grown under nonadherent conditions in vitro in the presence and absence of
Matrigel. (iii) Confocal image of an fSTR polyclonal sphere derived by mixing fSTR cells from WT and actin-eGFP transgenic embryos showing vimentin
immunofluorescence (red), nuclear counterstain DAPI (blue), and actin-eGFP (green). The scale bar represents 50 mm.
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Fetal Mammary Stem Cells and Breast Cancercontaining or lacking specific ErbB ligands and FGF. Cultures
lacking both EGF and FGF produce no spheres, while either
EGF or FGF stimulated fMaSC-derived sphere formation (Fig-
ure 5B). Heregulin 1 (Hrg1, neuregulin, Neu differentiation factor),
an ErbB ligand with a preference for ErbB3 or ErbB4, stimulated
sphere growth in the absence of EGF and FGF (Figure 5B)
(Britsch, 2007). The effects of these ligands were additive
(SFE 10% for EGF/FGF/HRG), and Hrg1 showed the most
dramatic effect on large sphere production (Figure 5B). By
contrast, GDNF, which is not represented in the hypothesized
interaction network, did not stimulate sphere formation
(Figure 5B).
Consistent with the above results, ErbB and FGFR kinase
antagonists inhibited fMaSC-derived sphere growth (Figures
5C and 5D and Figure S5). Lapatinib is a reversible and highly
specific ErbB1/2 dual tyrosine kinase inhibitor (Rusnak et al.,
2001), while neratinib is an irreversible pan-ErbB kinase inhibitor
(Rabindran et al., 2004). Lapatinib and neratinib inhibited sphere
growth with a similar dose-dependence as observed for Her2
overexpressing human mammary cells with documented sensi-
tivity to these agents (Figures 5C and 5D) (Wang et al., 2006). As
these drugs have nonoverlapping potential off-target effects
(Karaman et al., 2008; Rabindran et al., 2004; Rusnak et al.,
2001), it is most likely that their effects on sphere growth derive
from ErbB pathway antagonism. However, it remains to be
determined whether inhibition of one specific ErbB receptor
accounts for the observed effects on sphere growth or whether
redundancy in this family necessitates inhibition of multiple
receptors for effective fMaSC growth antagonism in vitro. Alto-
gether, these findings substantiate the importance of ErbB and
FGF signaling in fMaSC-derived sphere growth in vitro, and
they indicate the presence of functionally relevant gene content
in the microarray-derived fetal mammary signatures.
Molecular Links between Fetal Mammogenesis
and Breast Cancer
Cancer-associated genes (ErbB2,Met,CXCR4, etc.) were prom-
inent among the fetal signatures and pathway analyses and in
unsupervised gene set enrichment analyses (Figures 4 and 5,
Figure S5, and Table S4). Therefore, we determined whether
fetal gene expression signatures were enriched in particular
human breast cancer intrinsic subtypes by using archival tumor
microarray data from two independent compendia and human
orthologs of the fMaSC and fSTR signature genes (Figure 6, Fig-
ure S6, and Table S6) (Ben-Porath et al., 2008; Prat et al., 2010).
Enrichment for the fMaSC signature was concentrated among
tumors designated as basal-like, which tend to be poorly differ-
entiated and stem-like (Ben-Porath et al., 2008; Mizuno et al.,
2010). In addition, many Her2+ tumors showed significant
enrichment for the fMaSC signature (Figure 6A and Figure S6A).(B) Quantification of clonal, primary fMaSC-derived sphere growth, secondary
indicate standard deviation (SD).
(C) Confocal immunofluorescence analysis of spheres derived from the fMaSC p
nuclear counterstain DAPI (blue) and tabular summary of sphere types observed.
K8 (i.e., middle of the sphere), while type 2 spheres consist mainly of cells coexp
bars represent 25 mm. The inset shows secondary antibody control (the scale ba
(D) Summary of the percentage of cells in the fMaSC and fSTR populations exp
See also Figure S2.
CeEnrichment for the fSTR signature often correlated with tumor
subtypes characterized by low proliferation and favorable prog-
noses (Figure 6A and Figure S6A) (Sørlie et al., 2001). However,
claudin-low and metaplastic-like tumors, which have also been
suggested to be stem-like (Hennessy et al., 2009; Perou et al.,
2010; Prat et al., 2010) were generally enriched for the fSTR
signature and depleted for the fMaSC signature (Figure 6A and
Figure S6A). Breast cancers showing enrichment for fSTR signa-
tures showed nearly identical enrichment patterns for aMaSC
signatures (Figure S6B), consistent with the significant gene
overlap of aMaSC and fSTR signatures noted above (Figure 4B).
Previous studies have used signatures derived either directly
from breast cancer array data or from specific biological
contexts, such as serum stimulation of fibroblasts (simulating
wound healing), to classify breast cancers into different tumor
types with distinct clinical features (Fan et al., 2006). The fMaSC
signature exhibits relatively little overlap with these signatures
(6.5% of fMaSC genes shared, Figure 6B and Table S7).
While, the signatures compared in Figure 6B have significant
representation of ER- and/or proliferation-associated genes
(Fan et al., 2006; Wirapati et al., 2008), the fMaSC and fSTR
signatures have little representation of proliferation genes (Fig-
ure 6B) because this is a characteristic they share, leading to
exclusion from their comparative profiles. Furthermore, removal
of the few residual proliferation-related genes from the fMaSC
and fSTR signatures did not markedly alter the observed tumor
enrichments (Figure 6A and Figure S6A). We cannot rule out
the possibility that fetal-like molecular programs are also
invoked by other proliferative states in the mammary gland, for
instance at puberty or pregnancy or during outgrowth of trans-
planted material. Regardless, the fMaSC and fSTR signatures
clearly identify a distinct group of genes associating fetal
mammary gland biology and fMaSCs with specific molecularly
defined breast cancer subtypes (Figure 6B).
Fetal Gene Subsets Identify Patients with Diverse
Prognoses in Archival Tumor Samples
The fMaSC and fSTR signatures can be subdivided into gene
expression modules showing coordinated expression across
multiple tumors with hierarchical clustering analysis (Figures
S6C and S6D). We then correlated these subsignatures with
breast cancer grade, progression, subtype, or prognosis (Fig-
ure 6C and Figures S6 and S7). We subdivided the fMaSC and
fSTR signatures into five and four subsignatures, respectively,
by using the 96 genes with the greatest variance in the compen-
dium. The genes comprising these enriched subsets represent
diverse biological processes previously implicated in cancer,
including immune response (fMaSC-iii, fSTR-ii), cell survival
(fMaSC-v), and wounding (fSTR-ii, fSTR-iv) (Figures 6C and 6E
and Table S7) (Chang et al., 2004; Perou et al., 2000; Rodyand tertiary sphere growth, and fSTR-derived sphere growth. The error bars
opulation showing the expression of K8 (red), K14 (green), or both (yellow) with
Type 1 spheres consist of cells expressing either K14 (i.e., sphere periphery) or
ressing K8 and K14 (yellow cells). Inset, secondary antibody control. The scale
rs represent 50 mm).
ressing K8, K14, and/or vimentin. The error bars indicate standard deviation.
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Figure 3. Differential Gene Expression Profiling of fMaSC, fSTR, and aMaSC Populations
(A) Illustration of sorted populations, Pearson correlation among biological replicates for each cell type, and heatmaps illustrating the identification of differentially
expressed genes (SAM; FDR < 10%).
(B) qRT-PCR analysis of select stem cell and developmental genes in the fMaSC population relative to fSTR. Error bars indicate standard deviation.
(C) Expression levels of a representative selection of genes determined by microarray and by qRT-PCR. The expression level in the fMaSC relative to the fSTR is
plotted as the fold difference in expression. Fold differences in gene expression were calculated for RT-PCR assuming ideal amplification (fold change = 2DCt) and
for Nimblegen array data with the normalized probe intensities (fold change = DLog2(intensity)). Data were normalized to hypoxanthine-guanine phosphor-
ibosyltransferase. Despite differences in the dynamic range of the two techniques, the pattern of differential expression between the fMaSC and fSTR determined
by array was consistent with the pattern determined by qRT-PCR.
(D) Microfluidics-based, single-cell, qRT-PCR analyses of cells from the fMaSC population. Right: examples of single cells coexpressing various keratins and the
mesenchymal marker, vimentin. See also Table S4.
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(fMaSC-ii, fMaSC-v, and fSTR-iii) and adhesion (fMaSC-iv and
fSTR-iii), which have been less extensively investigated in
cancer, were also represented (Figure 6E and Table S7).190 Cell Stem Cell 10, 183–197, February 3, 2012 ª2012 Elsevier IncThese fetal subsignatures exhibit prognostic relevance in
archival breast cancer array data (Figures 6C and 6D and Fig-
ure S7). For instance, enrichment for signature fMaSC-ii or
repression of signature fSTR-iv correlated with Her2+ and.
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Fetal Mammary Stem Cells and Breast Cancerbasal-like tumors, high grade, and reduced probability of patient
survival (Figure 6C and Figure S7). This observation is consistent
with the predicted outcome of these intrinsic subtypes (Sørlie
et al., 2001). In addition, multivariate survival analyses based
on enrichment for the fetal subsignatures showed prognostic
value beyond commonly used clinical metrics such as ER status,
tumor size, grade, and lymph node status (Figure 6D). The bio-
logical and prognostic relevance of the signatures described
here is a function of their biological origin, as randomized signa-
tures are not enriched in a sufficient number of tumors to enable
tumor classification and subsequent survival analysis (Figure 6A
and Figure S7). However, it may be possible to derive alternative
fetal gene subsignature groupings exhibiting enhanced prog-
nostic value, predictive value, or additional functional biological
insight through the use of alternative statistical approaches. As
approximately 60% of the genes comprising these fetal sub-
signatures are specifically upregulated relative to the aMaSC
population (Tables S4, S5, and S7), these signatures provide
new candidates for therapeutic and prognostic strategies that
would probably be missed by deriving signatures from the
resting adult gland.
DISCUSSION
The existence of fMaSCs has been inferred from studies demon-
strating that intact mammary epithelium obtained from as early
as E13.5 can fully reconstitute the mammary gland (Sakakura
et al., 1979). However, these studies did not quantify or purify
mammary stem cells. This left a substantial gap in our under-
standing of mammary biology and precluded elucidation of the
long predicted molecular and genetic links between fetal
mammary development, stem cells, and breast cancer (Howard
and Ashworth, 2006). Here, we provide the first quantitative
assessment of mammary stem cell activity during fetal mammo-
genesis, obtain fetal mammary gene expression profiles and
evaluate their relationship to breast cancer.
Our studies reveal the surprising finding that mammary rudi-
ments from E15.5 and earlier contain few if any functional
fMaSCs. We observed a 200-fold increase in fMaSC activity
during the course of fetal mammogenesis that parallels the
change in cellular context as the proliferating mammary epithe-
lium begins to invade through the adjacent mesenchyme and
interacts with the fat pad microenvironment (Veltmaat et al.,
2003). While proliferation during mammogenesis probably
contributes to fMaSC abundance, the 9-fold increase in fMaSC
frequency between E15.5 and E16.5 is difficult to explain solely
by cell division. Instead, we propose that stromal interactions
during this interval generate signals that act on precursor cells
to engender the stem cell competence we assay by transplanta-
tion. It is noteworthy that a recent in vivo lineage tracing study
also demonstrated the existence of bipotent mammary stem
cells in late embryogenesis and suggested a restriction to unipo-
tent stem/progenitor activity occurring shortly after birth (Van
Keymeulen et al., 2011).
The hypothesis that context and extrinsic cues underlie fMaSC
functional identity is consistent with studies showing the impor-
tance of cell-cell and cell-matrix interactions and locally
produced soluble factors for stem cell function (Jones and
Wagers, 2008; Spradling et al., 2001). Direct niche interactionsCealso maintain the stem cell state within various tissues and
organisms, such as Drosophila testes and mammalian hair folli-
cles, bonemarrow, testes, and intestines (Spradling et al., 2001).
Stem cell niches also produce soluble factors, including Wnt,
FGF, TGFb, and EGF ligands, which promote or maintain the
stem cell state (Spradling et al., 2001; Zeng and Nusse, 2010).
Importantly, the involvement of multiple ErbB receptors and
their ligands in mammary morphogenesis (Jackson-Fisher
et al., 2008; Jackson-Fisher et al., 2004; Tidcombe et al., 2003;
Wansbury et al., 2011) is consistent with our observations impli-
cating this family in fMaSC function in vitro. The ErbB kinase
inhibitor studies reported here and gene knockout studies
showing that mammary gland development is impaired to
differing degrees in various ErbB knockout mouse strains (Jack-
son-Fisher et al., 2008; Jackson-Fisher et al., 2004; Tidcombe
et al., 2003) suggest that interactions with relevant stromal
components and growth factor gradients may be important for
inducing stem cell activity during development.
The fMaSC population includes cells that coexpress luminal
and myoepithelial markers with vimentin. The expression of
vimentin within epithelial cells of the human adult mammary
gland is normally restricted to the myoepithelial lineage and
has not been reported to occur in concert with luminal keratin
expression (Anbazhagan et al., 1998; Mørk et al., 1990). Interest-
ingly, forced coexpression of luminal keratins 8 and 18 with
vimentin in human breast cancer cells in vitro increases motility,
invasiveness, and proliferation (Hendrix et al., 1997). Similarly,
basal-like breast cancers frequently exhibit an undifferentiated
phenotype and coexpress myoepithelial and luminal epithelial
keratins and vimentin (Livasy et al., 2006). Our data suggest
that the coexpression of myoepithelial and luminal keratins and
vimentin may typify an uncommitted, embryonic, fMaSC-like
state. We suggest that the partial epithelial to mesenchymal
transition (EMT) commonly observed during aggressive tumori-
genesis may represent a reversion to an embryonic-like state
resembling the fMaSC and/or fSTR compartments (Hanahan
and Weinberg, 2011). EMT has long been recognized as an
essential embryonic process required for development beyond
the blastula stage (Hay and Zuk, 1995) and may also promote
a stem cell-like state in breast cells (Mani et al., 2008; Thiery
and Sleeman, 2006).
fMaSC signatures are derived from cells with a defined bio-
logical role and have not been analyzed previously for their
relationship to cancer. Other signatures representing biological
processes, such as wound healing and immune response,
have proven useful for gauging the risk of recurrence in some
breast cancer subtypes (Chang et al., 2004; Rody et al., 2011).
Thus, we anticipated that our analyses would uncover new
genes and pathways related not only to fetal mammary develop-
ment and fMaSC function but also to breast cancer. Our results
suggest that this resource contains new gene sets with prog-
nostic value that may also be useful for predicting which patients
will respond to certain treatment strategies. For example,
patients receiving ErbB (Her)-targeted therapies, such as her-
ceptin (Trastuzumab) and lapatinib, are selected based on
ErbB2 gene amplification and high-level ErbB2 expression within
their tumors (Jacobs et al., 1999). However, in the NSABP-31
clinical trial, some patients confirmed by clinical standards to
be ErbB2 negative responded to the ErbB targeted treatmentll Stem Cell 10, 183–197, February 3, 2012 ª2012 Elsevier Inc. 191
Figure 4. Unique Gene Content in the E18.5 Fetal Mammary
(A) qRT-PCR analysis of select stem cell and developmental genes in fMaSC relative to the E15.5 mammary rudiment. N.S is an abbreviation for no signal.
(B) Overlap of fMaSC signature genes and their orthologs with previously reported normal adult mammary signatures. Upper: mouse signatures (Lim et al., 2009;
Pece et al., 2010). Lower: shows hMaSC and hStromal signatures (Lim et al., 2010) and a signature from cultured hMaSCs (Lim et al., 2009; Pece et al., 2010);
p values represent the hypergeometric probability based on all 20,309 probes in the mouse array and 19,828 probes in the human arrays.
(C) Identification of genes unique to fMaSC and fSTR populations (Venn diagrams) and clustering of expression array data for these genes for fMaSC (f), fSTR (s),
aMaSC (a), E15.5 mammary rudiments (b, buds), and lineage-depleted adult mammary epithelium (e) (heat maps).
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Figure 5. Prediction and Validation of Nonautonomous Signaling in fMaSC Function
(A) A model constructed from fetal gene signatures filtered for receptors and ligands with the GeneGo pathway analysis platform. The model illustrates candidate
protein-protein interactions including receptor-ligand pairs expressed reciprocally in the fMaSC (left) and fSTR (right) populations. Additional gene products of
interest predicted to interact with the network are also indicated (gray). The map suggests that ErbB signaling, among other pathways, may play a prominent role
in fMaSC function.
(B) Quantification of fMaSC-derived spheres in the absence and presence of growth factors suggested by the model in (A).
(C) Quantification of fMaSC-derived sphere growth upon inhibition of ErbB1/2 signaling by either lapatinib or inhibition of ErbB1/2/4 signaling by neratinib.
*p < 0.05, Student’s t test.
(D) Dose-response curves to lapatinib and neratinib in resistant human BT549 and sensitive MCF10A/HER2 cell lines (Wang et al., 2006; Weigelt et al., 2010).
All error bars indicate SD. See also Figure S5.
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Fetal Mammary Stem Cells and Breast Cancerregimen (Paik et al., 2008). Our results show that fMaSCs, which
would probably also be designated as ErbB2 negative with
accepted clinical guidelines, are sensitive to ErbB pathway(D) Gene ontology enrichment analysis of genes unique to the fMaSC and fSTR
globe represents the number of genes in the category. Significantly enriched cate
adjusted FDR = 5%). The organic layout algorithm used (Cytoscape) allows visua
enriched for each signature type. The most highly enriched categories are color
contributing to the most enriched ‘‘biological process’’ for each population are li
Ceinhibitors. We speculate that tumors acquiring an fMaSC-like
state will rely on ErbB pathway signaling and, therefore, be sensi-
tive to ErbB antagonists despite being clinically designated assignatures. Each globe represents an ontological category and the size of the
gories are color coded in red for fMaSC and blue for fSTR (Benjamini-Hochberg
lization of dense ontological data and the observation that many categories are
coded in orange. The categories with the lowest p values and the gene names
sted to the right. See also Figure S4 and Tables S4 and S5.
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Figure 6. Fetal Mammary Gene Expression Patterns Provide Molecular Links to Human Breast Cancers
(A) Significant correlation between fMaSC and fSTR gene signatures and human breast cancers (n = 337) (Prat et al., 2010) are indicated by horizontal bars, each
representing the gene expression profile from an individual tumor sample. Red bars indicate tumors enriched in fetal signature expression; blue bars indicate
signature repression. Black bars indicate no significant correlation. Larger colored squares illustrate the trend for each intrinsic subtype. For comparison,
a randomized signature of equivalent size and a proliferation signature (Ben-Porath et al., 2008) are shown.
(B) A comparison of several signatures and clinical metrics by significance of gene overlap. Most signatures are closely related and are significantly associated
with ER (yellow box) or Proliferation (AURKA; red box) related signatures. Because of its size, the small OncotypeDX signature showsmodest significance values
for the proliferation group, although it includes several proliferation ER- and Her2-related genes. The fMaSC signature (green box and arrows) is relatively unique
and shows no significant overlap with proliferation or ErbB2/Her2-related signatures (blue) and relatively low association with ER-related signatures.
(C) Significance of enrichment for subsignatures among diverse breast cancers in a large microarray compendium (n = 1,211) (Ben-Porath et al., 2008).
Enrichments according to subtype and grade are indicated by colored squares that represent probabilities for the percentage of tumors enriched or repressed in
each annotation group. Genes comprising each subsignature are listed.
(D) Subsignatures showing significance (A, p% 0.1) or trends (>, p% 0.25) in multivariate analysis are graphed for models including the following categorical
clinical variables: A: ER status, grade, lymph-node status, tumor size; B: grade, lymph-node status and tumor size; C: ER status, lymph-node status and size
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Fetal Mammary Stem Cells and Breast CancerErbB2 negative. The disproportionate representation of prolifer-
ation-, ER-, and Her2-related signaling in many existing prog-
nostic signatures may mask less prominent yet critical signaling
pathways that can be uncovered by studying normal develop-
mental paradigms such as the fMaSC and fSTR states that are
perturbed in cancer.
Links between embryogenesis and tumorigenesis were first
proposed in 1838 by Mu¨ller as the stem cell origin of cancer
and then extended by Durante and Conheim’s hypothesis that
elements remaining in an undifferentiated embryonic state or
that reacquire characteristics of this state generatemalignancies
(Brewer et al., 2009; Sell, 2010). Subsequent descriptions of
onco-fetal proteins, identification of embryonic stem cell genes,
splice isoforms, microRNAs, and embryonic metabolism in
cancer add credence to this concept (Brewer et al., 2009;
Christofk et al., 2008; Powers and Mu, 2008; Sell, 2010). Our
identification of a population of fMaSCs and associated
stroma with gene expression signatures enriched in different
types of breast cancer further support the importance of under-
standing both components and their interaction during cancer
progression.
We suggest that cells resurrecting the programs that govern
fetal tissue stem cells and fetal stroma may subsequently fuel
tumor progression in the adult. This raises the question of how
cells eliciting such programs arise during tumor progression. In
some breast cancers, oncogenic lesions, such as loss of p53,
may impart developmental plasticity, either directly or through
reprogramming of tumor cells to more primitive states, including
those resembling fMaSC or fSTR (Mizuno et al., 2010; Spike and
Wahl, 2011). In this regard, the gene expression network we re-
port involving both the fMaSCs and their associated stroma will
provide a resource for generating newmolecular hypotheses link-
ing development and cancer, developing new diagnostic and
prognosticmetrics, and identifying candidate therapeutic targets.
EXPERIMENTAL PROCEDURES
Mice and Embryos
CD-1 and CB17-SCID were purchased from Charles River. Actin-eGFP mice
were maintained on a CD-1 mixed background or pure C57BL/6J (Jackson
Labs).
Cell Preparation
Adult mammary glands were dissociated according to the Stem Cell Technol-
ogies (SCT) protocol. For fetal mammary glands, collagenase/hyaluronidase
digestion time was reduced to 90 min and the trypsin treatment was omitted.
Flow Cytometry
Single-cell suspensions were incubated with 40,6-diamidino-2-phenylindole
(DAPI) and the following antibodies: Fc receptor (2.4G), biotinylated CD31/
CD45/TER119 cocktail, CD24-PE (M1/69), CD49f-FITC (all from SCT) and
streptavidin-PerCPcy5.5 (BD Biosciences).
Mammary Transplantation
Mammary transplantation (Deome et al., 1959) was carried out with pulled-
glass capillaries and mouth pipetting. Transplanted glands were evaluated
6–12 weeks postsurgery.(NKI295). A positive (or red) value indicates a poorer prognosis, while a negativ
negative tumors is shown in model A (versus fMaSC-i) for comparison. The fo
repression; Ø = no significant signature enrichment and/or depletion. Error bars
(E) Biological functions associated with gene constituents of the subsignatures (g
CeImmunofluorescence
Wholemounts, paraffin sections, OCT sections, or cytospinswere stainedwith
antibodies to: keratin 14 (AF-64, Covance, 1:1,000), keratin 8 (Troma-1, DSHB,
1:100), CD24 (M1/69, BD Biosciences, 1:1,000), CD49f (GoH3, BD Biosci-
ences, 1:1,000), casein (a gift from G. Smith and D. Medina, 1:25), vimentin
(AB5733, Chemicon, 1:1,000) and ErbB2 (29D8, Cell Signaling, 1:500).
3D, In Vitro Culture
For suspension mammosphere culture, freshly sorted cells were plated on
ultralow-adherence plates (Corning) at 1000 cells/cm2 in Epicult-B mouse
media containing B-supplement, rhEGF, rhbFGF, heparin, and penicillin/strep-
tomycin. For the 2%Matrigel culture, cells were plated on ultralow-adherence
plates (Corning) at 1000cells/cm2 in mammosphere media supplemented with
2% Matrigel (growth factor reduced, BD Biosciences). For the 100% Matrigel
culture, freshly sorted cells were seeded on top of a 30 ml bed of Matrigel
(growth factor reduced) in 2% Matrigel media. Vehicle (DMSO), lapatinib (LC
Laboratories), neratinib (HKI-272, Pfizer) or FGFR inhibitor (PD173074, gift
from the Verma lab, Salk Institute) were added at the indicated doses. For
the clonal sphere culture, single cells were sorted into 96-well, low-adherence
plates at a single cell per well density in 2%Matrigel media. For the eGFP+ and
eGFP mixing experiments, The eGFP+ and eGFP fMaSC and fSTR popula-
tions were mixed in a 1:1 or 1:4 ratio. fMaSCs were seeded at low density on
top of Matrigel (growth factor reduced) in 2% Matrigel media and fSTR cells
were seeded at both low and high densities in mammosphere media.
Microarray and Bioinformatic Analysis
RNA was linearly T7-amplified, and gene expression was measured with
a Nimblegen Array (12x135k MM9; Roche Nimblegen). The data are available
at the gene expression omnibus at http://www.ncbi.nlm.nih.gov/ under acces-
sion GSE27027. Data were RMA normalized and processed with Excel, TIGR-
MeV, Genomica, Cytoscape and MedCalc softwares, and the DAVID website.
Differential expression was determined with SAM at FDR < 10% (Tusher et al.,
2001). Detailed experimental and statistical methods accompany this manu-
script as supplemental information.
ACCESSION NUMBERS
The gene expression omnibus accession number for the microarray expres-
sion data reported in this paper is GSE27027.
SUPPLEMENTAL INFORMATION
Supplemental Information include six figures and eight tables and can be
found with this article online at doi:10.1016/j.stem.2011.12.018.
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